Effects of a D2 receptor agonist RO 41–9067 alone and with clonidine on sleep parameters in the rat

doi:10.1016/0091-3057(95)02023-3

Pharmacology Biochemistry and Behavior

Volume 53, Issue 2, February 1996, Pages 291-296

https://doi.org/10.1016/0091-3057(95)02023-3 Get rights and content

Abstract

The effects of RO 41–9067, a D₂ dopamine receptors agonist, on different sleep parameters were studied in the rat. RO 41–9067 dose dependently decreased paradoxical sleep, and only at the higher dose increased waking during the light period. In contrast, the higher dose of RO 41–9067 increased paradoxical sleep and decreased waking during the dark period. Finally, the combination of RO 41–9067 and clonidine significantly prevent the decrease of total sleep time and paradoxical sleep found after clonidine alone. These results, compared with those of classical D₂ dopamine receptors agonists, suggest an action for RO 41–9067 on D₂ dopamine receptors depending on the cerebral structure, a different action particularly on the striatum and/or on the structures responsible for paradoxical sleep. An active role for D₂ dopamine receptors and an interaction between noradrenergic and dopaminergic systems in the regulation of sleep is proposed.

References (26)

R.M. Kessler et al.
High affinity dopamine D₂ receptor radioligand. 2. [¹²⁶]Epidepride, a potent and specific radioligand for the characterization of strial and extrastrial dopamine D₂ receptors
Life Sci.
(1991)
A. Mc Rae-Degueurce et al.
Serotonin and dopamine afférents to the rat locus coeruleus: Biochemical study after lesioning of the ventral mesencephalic tegmental-A10 region and the raphé dorsalis
Brain Res.
(1983)
J.M. Monti et al.
Effects of the selective dopamine D₂ receptor agonist, quinpirole on sleep and wakefulness in the rat
Eur. J. Pharmacol.
(1989)
H.A. Robertson et al.
Synergistic and persistent interaction between the D₂ agonist, bromocriptine, and the D₁ selective agonist, CY 208-253
Brain Res.
(1992)
B. Beaufils
Le système dopaminergique mésencéphalique. Implications pour le traitement neuroleptique
Encéphale
(1990)
C. Belzung et al.
Behavioral Effects of RO 41–9067: A novel D₂ dopamine receptor agonist
Drug Dev. Res.
(1992)
D.B. Boivin et al.
Effects of bromocriptine in human narcolepsie
Clin. Neuropharmacol.
(1993)
C. Cianchetti et al.
Suppression of REM and delta sleep by apomorphine in man: A dopamine mimetic effect
Psychopharmacology (Berlin)
(1980)
M. Hamon
Dopamine et serotonine. Implication dans les effets centraux des psychotropes
Encephale
(1989)
E. Hartmann et al.
Norepinephrine and dopamine differential effects in the rat

D. Herve et al.

Interactions réciproques entre les systèmes noradrénergiques et dopaminergiques dans le cortex préfrontal et l'aire tegmentale ventrale

Encephale

(1989)

I. Hilakivi

Biogenic amines in the regulation of wakefulness and sleep

Med. Biol.

(1987)

D.A. Hopkins et al.

Substantia nigra projections to the reticular formation, superior colliculus and central gray in the rat, cat and monkey

Neurosci. Lett.

(1976)

Cited by (16)

Neonatal tricyclic antidepressant clomipramine treatment reduces the spike-wave discharge activity of the adult WAG/Rij rat
2012, Brain Research Bulletin
Citation Excerpt :
SWDs were almost completely missing during REM sleep (Coenen et al., 1991; Drinkenburg et al., 1991; Sarkisova and Van Luijtelaar, 2011). Decreased activity of the serotonergic and/or noradrenergic system or increased cholinergic transmission may cause increased amount of REM sleep (Thase, 2006), while enhanced dopamine level may decrease REM sleep (Python et al., 1996). Neonatal clomipramine treatment reduces (i) the expression of serotonin transporter mRNA in the dorsal raphe nuclei (Hansen and Mikkelsen, 1998), (ii) the number of serotonin transporter-immunoreactive fibres in the cortex (Maciag et al., 2006), (iii) the tryptophan hydroxylase immunoreactivity in the raphe nuclei (Maciag et al., 2006) and (iv) the firing frequency of the dorsal raphe neurons (Yavari et al., 1993) in adult rats.
Recently it was revealed that the absence-like epileptic activity of the WAG/Rij (Wistar Albino Glaxo/Rijswijk) rat is associated with depression-like behavioural symptoms. Whether these depressive-like symptoms are accompanying epileptic activity (manifested in spike-wave discharges, SWDs, in the EEG) or whether they are causative for each other are open questions. Neonatally administered tricyclic antidepressant clomipramine is a well characterized animal model of major depression. It evokes behavioural symptoms of depression and changes sleep pattern in normal adult rats. We investigated whether in the WAG/Rij rat the neonatally administered clomipramine would aggravate the depression-like behavioural symptoms and the SWD activity. Male WAG/Rij pups from postnatal day 8 (PD8) to PD21 were treated with clomipramine (20 mg/kg) or saline (control animals) twice daily intraperitoneally (i.p.). In the 8 months old rats, sleep parameters and sucrose solution intake (as hedonic index) as well as the SWD activity were measured. While the neonatal clomipramine treatment significantly increased the rapid eye movement sleep (REM) amount and decreased the sucrose preference score, it surprisingly attenuated the adult (8 months old) SWD activity. We concluded that neonatal clomipramine treatment produced aggravation of depression-like symptoms while decreased the SWD activity in the adult (8 months old) WAG/Rij rat.
D<inf>1</inf>/D<inf>2</inf> receptor-targeting L-stepholidine, an active ingredient of the Chinese herb Stephonia, induces non-rapid eye movement sleep in mice
2009, Pharmacology Biochemistry and Behavior
L-stepholidine, an active ingredient of the Chinese herb Stephonia, is the first compound known to have mixed dopamine D₁ receptor agonist/D₂ antagonist properties and to be a potential treatment medication for schizophrenia. In schizophrenic patients insomnia is a common symptom and could be partly related to the presumed over-activity of the dopaminergic system. To elucidate whether stepholidine modulates sleep behaviors, we observed its effects on sleep–wake profiles in mice. The results showed that stepholidine administered i.p. at doses of 20, 40 or 80 mg/kg significantly shortened the sleep latency to non-rapid eye movement (non-REM, NREM) sleep, increased the amount of NREM sleep, and prolonged the duration of NREM sleep episodes, with a concomitant reduction in the amount of wakefulness. Stepholidine at doses of 40 and 80 mg/kg increased the number of state transitions from wakefulness to NREM sleep and subsequently from NREM sleep to wakefulness. However, stepholidine had no effect on either the amount of REM sleep or electroencephalogram power density of either NREM or REM sleep. Immunohistochemistry study showed that stepholidine dose-dependently increased c-Fos expression in neurons of the ventrolateral preoptic area, a sleep center in the anterior hypothalamus, as compared with the vehicle control. These results indicate that stepholidine initiates and maintains NREM sleep with activation of the sleep center in mice, suggesting its potential application for the treatment of insomnia.
Effects of selective dopamine D4 receptor antagonist, L-741,741, on sleep and wakefulness in the rat
2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry
The influence of the dopamine system upon sleep/wake states is not fully understood. To date, the role of dopamine D4 receptor has not been studied. The aim of this work is to study the influence of dopamine D4 receptor upon sleep/wake states in male rats. Male Wistar rats were implanted with electroencephalography and electromyography electrodes for sleep recording. Sleep/wake times were compared in rats first treated with control solution (vehicle) and the day after treated with a potent and highly selective D4 dopamine receptor antagonist. L-741,741 (1.5, 3, 6 mg/kg) or vehicle solution (10% DMSO in saline) was administered intraperitoneally at the beginning of the light period. Subsequently, 3 h of polysomnography were recorded and sleep–wake parameters evaluated. For statistical comparisons, Wilcoxon ranges test was performed. L-741,741 (1.5 mg/kg) only increased Light Slow Wave Sleep (SWS). 3 mg/kg enhanced Quiet Waking (QW) increasing number of episodes, whereas Active Waking (AW) was reduced decreasing mean episode duration. 6 mg/kg reduced number of episodes of Deep SWS and increased its latency. Light SWS was decreased reducing number of episodes and their duration. Total time spent asleep was reduced and time spent in AW was increased. REM latency was increased. These results suggest a role for D4 receptors in the regulation of wake and sleep.
Catecholamines and methods for their identification and quantitation in biological tissues and fluids
2002, Journal of Neuroscience Methods
Catecholamines act via dopaminergic-, and adrenergic receptors, and are involved in a variety of regulatory systems. They take part in regulation of the response to stress, psychomotor activity, emotional processes, learning, sleep and memory. Due to many catecholaminergic pathways, and a wide range of functions they are involved in, both in the central nervous system and in periphery, a development of the reliable techniques for their extraction and quantitation is essential. This paper presents an overview of the currently applied methodologies for catecholamines detection and identification in various biological samples.
Pergolide restores sleep maintenance but impairs sleep EEG synchronization in patients with restless legs syndrome
2002, Sleep Medicine
Background: The treatment with the long-acting dopamine D1/D2 receptor agonist pergolide has been proven as very effective in lowering the frequency of periodic leg movements (PLM) in patients with restless legs syndrome (RLS). To further investigate the influence of this potent dopaminergic drug on the microstructure of rapid eye movement (REM) and non-REM sleep EEG we established a quantitative analysis of the EEG data.
Methods: The study group consisted of 15 patients with primary RLS (mean age 57.1±10.1 years) who were a subgroup of patients within a double-blind randomized crossover treatment study with pergolide versus placebo. The polysomnographic recordings were analyzed visually and submitted to a quantitative EEG analysis (fast Fourier transformation).
Results: The pergolide treatment induced a significant reduction of the spectral power in the delta range (0.78–3.9 Hz; P<0.05; t-test) during SWS, as well as a significant reduction of PLMs. In addition, we observed a decrease in the sigma EEG activity (12.1–14.8 Hz; P<0.03) during non-REM sleep and stage 2 sleep. The visual sleep scoring revealed a significant increase in stage 2 sleep (P<0.005), whereas wakefulness was markedly diminished (P<0.001). The REM sleep parameters including the EEG power spectrum remained unchanged.
Conclusions: The treatment with pergolide markedly improved the sleep quality in RLS patients but did not restore SWS including the spectral power in the lower frequencies. Our results suggest that the dopamine agonist pergolide interferes with the subcortical mechanisms regulating the process of EEG synchronization during non-REM sleep.
Neurotoxic N-methyl-D-aspartate lesion of the ventral midbrain and mesopontine junction alters sleep-wake organization
1999, Neuroscience
The dorsal regions of the midbrain and pons have been found to participate in sleep regulation. However, the physiological role of the ventral brainstem in sleep regulation remains unclear. We used N-methyl-d-aspartate-induced lesions of the ventral midbrain and pons to address this question. Unlike dorsal mesencephalic reticular formation lesions, which produce somnolence and electroencephalogram synchronization, we found that ventral midbrain lesions produce insomnia and hyperactivity. Marked increases in waking and decreases in slow wave sleep stage 1 (S1), stage 2 (S2) and rapid eye movement sleep were found immediately after the lesion. Sleep gradually increased, but never returned to baseline levels (baseline/month 1 post-lesion: waking, 30.6±4.58%/62.3±10.1%; S1, 5.1±0.74/3.9±1.91%; S2, 46.2±4.74%/23.1±5.47%; rapid eye movement sleep, 14.1±3.15%/7.2±5.42%). These changes are comparable in magnitude to those seen after basal forebrain lesions. Neuronal degeneration was found in the ventral rostral pons and midbrain, including the substantia nigra, ventral tegmental area, retrorubral nucleus, and ventral mesencephalic and rostroventral pontine reticular formation.
We conclude that nuclei within the ventral mesencephalon and rostroventral pons play an important role in sleep regulation.

View all citing articles on Scopus

View full text

ArticleEffects of a D2 receptor agonist RO 41–9067 alone and with clonidine on sleep parameters in the rat

Abstract

Life Sci.

Brain Res.

Eur. J. Pharmacol.

Brain Res.

Le système dopaminergique mésencéphalique. Implications pour le traitement neuroleptique

Encéphale

Behavioral Effects of RO 41–9067: A novel D2 dopamine receptor agonist

Drug Dev. Res.

Effects of bromocriptine in human narcolepsie

Clin. Neuropharmacol.

Suppression of REM and delta sleep by apomorphine in man: A dopamine mimetic effect

Psychopharmacology (Berlin)

Dopamine et serotonine. Implication dans les effets centraux des psychotropes

Encephale

Norepinephrine and dopamine differential effects in the rat

Interactions réciproques entre les systèmes noradrénergiques et dopaminergiques dans le cortex préfrontal et l'aire tegmentale ventrale

Encephale

Biogenic amines in the regulation of wakefulness and sleep

Med. Biol.

Substantia nigra projections to the reticular formation, superior colliculus and central gray in the rat, cat and monkey

Neurosci. Lett.

Article
Effects of a D₂ receptor agonist RO 41–9067 alone and with clonidine on sleep parameters in the rat

Behavioral Effects of RO 41–9067: A novel D₂ dopamine receptor agonist